Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Recent Scientific Advances in Vaccine Platforms
share announcement

Recent Scientific Advances in Vaccine Platforms

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1606

Special Issue Editors

Prof. Dr. Pan Tao

E-Mail Website
Guest Editor
College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
Interests: infectious diseases; vaccine platforms; vaccine development; bacteriophages; bacteriophage–host interaction; phage therapy; phage technologies
Special Issues, Collections and Topics in MDPI journals
Dr. Jingen Zhu

E-Mail
Guest Editor
Department of Biology, Catholic University of America, Washington, DC, USA
Interests: vaccine vectors; virus-like particle (VLP); mucosal vaccine; coronavirus vaccine development; gene and protein delivery/therapy; bacteriophage
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccines are recognized as being the most cost-effective means of preventing the spread of infectious diseases. However, the constant evolution of pathogens and the emergence of new infectious agents pose significant challenges to vaccine development. Due to the emergence of innovative vaccine platforms, vaccine development has made significant progress in recent years. This Special Issue of the journal Vaccines aims to showcase recent breakthroughs in the field of vaccine platforms, highlighting cutting-edge research that addresses challenges related to vaccine design. This collection will include articles exploring various vaccine platforms, such as mRNA-based vaccines, viral vector vaccines, nanomaterial vaccines, antigen delivery systems, novel adjuvants, etc. Key areas of focus will include the latest discoveries in the development of novel vaccine platforms, the optimization of current vaccine platforms and exploration of their mechanisms, and the application of vaccine platforms to improve vaccine efficacy and safety. Articles that explore the platforms’ roles at all stages of vaccine development, such as antigen identification, vaccine formulation, vaccine production, and vaccination, are welcome for submission.

Prof. Dr. Pan Tao
Dr. Jingen Zhu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • vaccine platforms
  • vaccine development
  • adjuvants
  • delivery systems
  • infectious diseases

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2768 KiB  
Article
Biological Characteristics of Feline Calicivirus Epidemic Strains in China and Screening of Broad-Spectrum Protective Vaccine Strains
by Longlong Cao, Jian Liu, Yongfan Li, Denglong Xie, Quanhui Yan, Qiuyan Li, Yiran Cao, Wenxin Du, Jiakang Li, Zijun Ye, Dengyuan Zhou, Chao Kang and Shengbo Cao
Vaccines 2023, 11(12), 1858; https://doi.org/10.3390/vaccines11121858 - 15 Dec 2023
Viewed by 1258
Abstract
Feline calicivirus (FCV) is one of the most important pathogens causing upper respiratory tract diseases in cats, posing a serious health threat to these animals. At present, FCV is mainly prevented through vaccination, but the protective efficacy of vaccines in China is limited. [...] Read more.
Feline calicivirus (FCV) is one of the most important pathogens causing upper respiratory tract diseases in cats, posing a serious health threat to these animals. At present, FCV is mainly prevented through vaccination, but the protective efficacy of vaccines in China is limited. In this study, based on the differences in capsid proteins of isolates from different regions in China, as reported in our previous studies, seven representative FCV epidemic strains were selected and tested for their viral titers, virulence, immunogenicity, and extensive cross-protection. Subsequently, vaccine strains were selected to prepare inactivated vaccines. The whole-genome sequencing and analysis results showed that these seven representative FCV strains and 144 reference strains fell into five groups (A, B, C, D, and E). The strains isolated in China mainly fall into groups C and D, exhibiting regional characteristics. These Chinese isolates had a distant evolutionary relationship and low homology with the current FCV-255 vaccine strain. The screened FCV-HB7 and FCV-HB10 strains displayed desirable in vitro culture characteristics, with the highest virus proliferation titers (109.5 TCID50/mL) at 36 h post inoculation at a dose of 0.01 MOI. All five cats infected intranasally with FCV-HB7 or FCV-HB10 strains showed obvious clinical symptoms of FCV. The symptoms of cats infected with the FCV-HB7 strain were more severe than those infected with the FCV-HB10 strain. Both the single-strain inactivated immunization and combined bivalent inactivated vaccine immunization of FCV-HB7 and FCV-HB10 induced high neutralizing antibody titers in five cats immunized. Moreover, bivalent inactivated vaccine immunization protected cats from FCV-HB7 and FCV-HB10 strains. The cross-neutralizing antibody titer against seven representative FCV epidemic strains achieved by combined bivalent inactivated vaccine immunization was higher than that achieved by single-strain immunization, which was much higher than that achieved by commercial vaccine FCV-255 strain immunization. The above results suggest that the FCV-HB7 and FCV-HB10 strains screened in this study have great potential to become vaccine strains with broad-spectrum protective efficacy. However, their immune protective efficacy needs to be further verified by multiple methods before clinical application. Full article
(This article belongs to the Special Issue Recent Scientific Advances in Vaccine Platforms)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop